Practical Considerations for Managing Patients on Tyvaso DPI (Treprostinil Inhalation Powder)

Area of Science:

• Pulmonary Hypertension
• Pharmacology
• Respiratory Medicine

Background:

• Pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD) necessitate comprehensive, guideline-directed management.
• Effective treatment involves active patient-provider collaboration to reduce disease impact and enhance survival.

Purpose of the Study:

• To provide an overview of inhaled prostacyclin therapy, focusing on practical considerations for managing PAH and PH-ILD patients treated with Tyvaso DPI.
• To offer recommendations for patient selection, education, monitoring, and side effect management for Tyvaso DPI therapy.

Main Methods:

• Review of inhaled prostacyclin therapy, specifically Tyvaso DPI.
• Compilation of recommendations from a panel of pulmonary hypertension advanced practice providers.

Main Results:

• Inhaled treprostinil formulations (Tyvaso and Tyvaso DPI) deliver therapy directly to lung vasculature, minimizing systemic exposure and adverse events.
• Tyvaso DPI presents a well-tolerated and convenient administration option for prostacyclin therapy.

Conclusions:

• Tyvaso DPI is an approved inhaled prostacyclin therapy for PAH and PH-ILD.
• Practical guidance is provided for optimizing patient care, including onboarding, monitoring, and managing side effects associated with Tyvaso DPI.